Apart from both in vitro and in vivo data supporting a critical role of EGFR in MUC1-mediated paclitaxel-resistance, our clinical study showed elevated expression of MUC1, EGFR, and IL-6 in post-chemotherapy cervical cancer tissues. This evidence concerns the gene MUC1 and cervical carcinoma.